Lianhuan Pharmaceutical: A subsidiary has obtained the "Drug Registration Certificate"

Lianhuan Pharmaceutical announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The approved drug this time is amlodipine besylate tablets, with specifications of 5mg and 10mg. The sales of amlodipine besylate tablets in hospitals nationwide in 2024 reached 1.216 billion yuan. Changle Pharmaceutical's R&D investment is approximately 3.83 million yuan. The acquisition of this certificate will further enrich the company and its subsidiary's product line, enhance market competitiveness, but is not expected to have a significant impact on the company's recent operating performance.